source
- Roche signs $1.53 billion licensing deal with Simcere for preclinical B-cell antibodyRoche announced a licensing agreement with China's Simcere Zaiming, paying $75 million upfront and potentially up to $1.53 billion in total, for worldwide rights to a preclinical trispecific antibo…
- Roche partners with China's Simcere Zaiming on $1.5 billion T-cell engager for B-cell diseasesRoche announced a licensing agreement with Simcere Zaiming, a subsidiary of China's Simcere Pharmaceutical Group, to develop a trispecific T-cell engager called SIM0660. The deal includes an upfro…